There is a boundary that matters more than most PMCF survey teams realize, and it does not show up clearly in a questionnaire. The question is not whether your survey is well-designed or scientifically sound. The question is whether it belongs inside the scope of post-market clinical follow-up at all.
Many manufacturers discover they are on the wrong side of that boundary only after a notified body raises it at review. Understanding where the line sits, and why it exists, is the kind of thing that prevents expensive course corrections mid-program.
Most PMCF survey design focuses on methodology: sample size, validated instruments, data integrity controls. Those all matter, and a purpose-built platform like Greenlight Guru Clinical is designed to support exactly those requirements. But methodology questions come after a more foundational one: is this activity legally and regulatorily a PMCF activity?
MDCG 2020-7, the EU guidance document that sets out the template and requirements for PMCF plans, is explicit on this point. PMCF activities must focus on confirming the safety and performance of the device within its approved intended purpose. Everything outside the approved intended purpose is outside the scope of PMCF. A rigorous survey design does not change that.
The approved intended purpose is the anchor. A class IIb wound care device approved for chronic wound management in adults cannot use a PMCF survey to explore its use in pediatric patients, even if some clinicians are using it that way in practice. A class III cardiovascular implant approved for a specific arterial indication cannot use a PMCF survey to probe adjacent vascular applications. What determines whether the activity qualifies as PMCF is the scope of your approved indication, not the questions you ask.
The distinction matters because the regulatory consequences are significant. Activity that falls outside the approved intended purpose is not PMCF. Under EU MDR Article 74, a post-market clinical investigation on a CE-marked device used outside its intended purpose carries the same ethics committee and competent authority requirements as a pre-market investigation. A survey form sent to participating sites is not a substitute for that process.
The off-label risk is not always a case of manufacturers deliberately trying to circumvent the rules. More often, it emerges from three specific situations.
The first is legacy devices with broad MDD intended purposes. Under the Medical Devices Directive (MDD), intended purpose definitions were often written more broadly than what EU MDR now requires. A manufacturer transitioning a legacy device to MDR may find that their current MDR-approved indication is narrower than what they were historically monitoring. Clinicians may still be using the device in ways that fall within the old MDD scope but outside the new MDR scope. If a survey includes questions about those uses, the activity crosses the boundary.
The second is exploratory endpoints. Manufacturers often want to understand not just whether their device is performing safely within its indication but whether it might perform well in adjacent ones. That curiosity is commercially understandable. A PMCF survey, however, is the wrong instrument for exploring it. Endpoints designed to generate hypotheses about new indications are investigational by nature, and they belong in a clinical investigation, not a PMCF program.
The third is broad recruitment criteria. Survey recruitment that is not tightly scoped to the approved patient population can pull in responses from outside the intended purpose almost inadvertently. If inclusion and exclusion criteria for participants are not written with the same rigor as a clinical investigation plan, the resulting data set will almost certainly contain off-label use data. Using that data to update technical documentation or a clinical evaluation report creates a compliance problem that is difficult to unwind.
A useful way to check whether a PMCF survey stays within its proper scope is to map every survey question to a specific element of the approved intended purpose as defined in the device's instructions for use.
If a question maps cleanly to a performance or safety attribute within the approved indication and approved patient population, it belongs in the survey. If a question generates information about uses, patient groups, or conditions outside the approved scope, it does not. There is no gray area between those two categories at a regulatory level, even if there is a gray area commercially.
The same logic applies to recruitment. The inclusion criteria for survey participants should describe the population that corresponds to the approved intended purpose. They should specify the indication, the device use setting, and the patient characteristics that are relevant to that indication. Exclusion criteria should explicitly exclude anyone whose use of the device falls outside those parameters.
Manufacturers sometimes hesitate to write tight inclusion and exclusion criteria for surveys because they worry about limiting the number of responses. That concern is real but secondary to the compliance risk of including out-of-scope participants. A smaller, well-scoped data set that can be used to update technical documentation is worth more than a larger one that cannot.
Class III and implantable device manufacturers face a specific version of this challenge. There is a perception in some parts of the industry that surveys are not appropriate for high-risk devices and that clinical investigations are always required. That perception is incorrect, but the conditions for surveys to serve as valid PMCF evidence for class III devices are stricter.
For a class III device, a general retrospective survey sits at level eight on the MDCG 2020-6 clinical evidence scale. That level is not sufficient for PMCF evidence on a high-risk device. A prospective, supervised survey with validated instruments, a statistically justified sample size, and full data integrity controls can reach level four, which is the standard notified bodies expect for PMCF evidence on class III devices. The methodology requirements for conducting a compliant PMCF survey are demanding, and scope compliance is a prerequisite before any of that methodology work starts.
The off-label boundary issue does not go away at level four. A methodologically sound level four survey that includes off-label use data is still non-compliant. The evidence quality and the scope compliance are separate questions, and both have to be answered correctly.
Notified bodies have confirmed in various forums that they view the choice of a validated, GCP-aligned data collection system as a positive signal. It demonstrates that the manufacturer understands the difference between a feedback form and a regulated data collection activity. Greenlight Guru Clinical is pre-validated for ISO 14155 and built to support both PMCF surveys and full clinical investigations in a single platform. That distinction matters regardless of device class, and it is one reason purpose-built tools have become the expected standard in notified body submissions.
Some evidence needs cannot be met by PMCF surveys under any design. When the objective is comparative clinical performance against an alternative treatment, when endpoints require procedures that go beyond routine clinical practice, or when the evidence need relates to a use outside the approved indication, a clinical investigation under EU MDR is the appropriate route.
Manufacturers sometimes arrive at the clinical investigation route reluctantly, having tried to design around it with a survey. The more productive approach is to make that determination at the planning stage, before committing design resources to a survey program that cannot deliver what is needed.
MDCG 2020-6 and MDCG 2020-7 read together provide a framework for that determination. MDCG 2020-6 defines the evidence levels and what each requires. MDCG 2020-7 defines the scope of PMCF activities. If the evidence need requires a level that a survey cannot reach given the device class and risk profile, or if the intended data collection falls outside the PMCF scope, the answer is a clinical investigation. Getting to that answer early is less expensive than discovering it after a notified body review.
For a broader view of how PMCF fits into your ongoing post-market obligations, the PMCF guide for EU MDR covers the full activity landscape alongside the evidence requirements.
BONUS RESOURCE: Click here to download our 15-in-1 Clinical Investigations Content Bundle.
If you are working through your PMCF evidence strategy, these related guides cover the specific components:
If you are mapping out PMCF data collection for your devices and want to understand where surveys fit within a compliant evidence strategy, Greenlight Guru Clinical is built specifically for this context, with pre-validated tools for both structured PMCF surveys and clinical investigations.